pleckstrin homology like domain family B member 3Genealiases: []
Q-omics provides the consensus-scored PHLDB3 profile across patient tissues and cancer cell-line models. PHLDB3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PHLDB3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PHLDB3 RNA expression shows 18,010 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where PHLDB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHLDB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHLDB3 survival associations across molecular data types. PHLDB3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHLDB3 RNA expression–survival associations across cancer types. High PHLDB3 expression shows unfavorable associations in KIRP, ACC, UCS, MESO and LGG, but favorable associations in PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PHLDB3 RNA expression.
This table summarizes PHLDB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PHLDB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHLDB3 shows lower tumor expression in KICH and higher tumor expression in KIRC, LUAD, COAD, LUSC and LIHC. The KIRC box plot shows higher PHLDB3 RNA expression in tumor versus normal tissue (log2 FC = +0.773, t-test p < 0.001).
This table shows molecular features associated with PHLDB3 in patient tissues and cancer cell lines. In patient samples, PHLDB3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHLDB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
